The Food and Drug Administration (FDA) has issued a new warning regarding potential confusion caused by the similar names of two drugs: Brintellix (vortioxetine), an antidepressant, and Brilinta (ticagrelor), a blood-thinning medication used to prevent death after heart attack or severe chest pain or to prevent a second heart attack.
According to Medscape, the FDA says it has received 50 reports since June about confusion around these brand names that has led to the wrong drug being prescribed or dispensed. The FDA is suggesting that doctors write out the indication for the drug and the generic name along with the brand name when prescribing either medication. Patients should also check their prescriptions to ensure they have the correct medication.
An article from TMLT’s the Reporter called “Drug name confusion” is also available for free download. The article describes how drugs are named; common look-alike and sound-alike (LASA) errors; and risk management considerations to help reduce errors.
About the Author
Laura Hale Brockway is Assistant Vice President of Marketing at TMLT and has more than 17 years of experience in communications, 15 of those years with TMLT. Ms. Brockway has also worked for Seton Healthcare Family and the Texas Academy of Family Physicians. An honors graduate of the University of Texas at Austin, Ms. Brockway holds an Editor in Life Science (ELS) certification from the Board of Editors in the Life Sciences. She is also a contributor to Ragan Communication’s PR Daily website and is the author of the blog, impertinentremarks.com. Laura Brockway can be reached at laura-brockway@tmlt.org.
More Content by Laura Hale Brockway
